Immunotherapeutic cancer vaccines: past, present and future

3 September 2021
kees_melief_large

Kees Melief, chief scientific officer of ISA Pharmaceuticals, provides an Expert View on why therapeutic cancer vaccines will be a success following many years of being out of favor.

After several decades of trials and tribulations, research and development of therapeutic cancer vaccines has seen renewed excitement around this promising approach. Typically, cancer vaccines are used to create an immune response via T-cells against an existing cancer, allowing the body to eliminate the cancer cells.

Past learnings: three mistakes

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology